Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04377620 · ClinicalTrials.gov registry record · Phase 3
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
A Phase 3 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 211
- Enrollment target
NCT04377620 is a Phase 3 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 211 participants.
The verdict
NCT04377620, a Phase 3 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 211 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.
Interventions
- DRUG Placebo
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2020-05-24 |
| Est. Completion | 2021-02-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04377620
The ClinicalTrials.gov registry entry for NCT04377620 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04377620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04377620 about?
NCT04377620 is a clinical study titled "Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)". The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.
What is the current status of trial NCT04377620?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 211 participants. The study started on 2020-05-24. Estimated completion is 2021-02-26.
What interventions are being tested in trial NCT04377620?
The interventions under investigation include: Placebo (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT04377620?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.